The European Medicines Agency has started a rolling review of Russia’s Sputnik V coronavirus (COVID-19) vaccine, bne IntelliNews reports, citing the Russian Direct Investment Fund (RDIF).
After being widely derided last year after the Russian authorities rushed through its registration before trials were complete, sentiment towards Russia’s first vaccine has improved enormously, especially after a peer-reviewed paper in leading British medical journal The Lancet cleared it as safe and effective at the start of February.
In addition to its high efficacy rates of around 95%, the Russian vaccine is easier to transport, as it doesn’t need to be …
